{"id":"tenofovir-disoproxil-lamuvidine-and-dolutegravir","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1486","moleculeType":"Small molecule","molecularWeight":"635.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tenofovir Disoproxil, Lamivudine, and Dolutegravir work together to inhibit viral replication by targeting different stages of the HIV life cycle. Tenofovir Disoproxil inhibits the reverse transcription of viral DNA, Lamivudine inhibits the reverse transcription of viral DNA, and Dolutegravir inhibits the integration of viral DNA into the host genome.","oneSentence":"Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Dolutegravir is an integrase strand transfer inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:04.311Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection in adults and pediatric patients"},{"name":"Prevention of mother-to-child transmission of HIV"}]},"trialDetails":[{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tenofovir Disoproxil, Lamuvidine and Dolutegravir","genericName":"Tenofovir Disoproxil, Lamuvidine and Dolutegravir","companyName":"Africa Health Research Institute","companyId":"africa-health-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Dolutegravir is an integrase strand transfer inhibitor. Used for Treatment of HIV-1 infection in adults and pediatric patients, Prevention of mother-to-child transmission of HIV.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}